Latest research on Dexmethylphenidate

Dexmethylphenidate is the dextrorotary form of methylphenidate. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Latest findings

d-threo-methylphenidate and l-threo-methylphenidate plasma levels were both quantified using fully validated liquid chromatographic methods with tandem mass spectrometry (LC MS/MS). [source, 2015]
The analytes d-threo-methylphenidate and l-threo-methylphenidate and their internal standard methylphenidate-d9 were extracted from a 0.200 mL aliquot of human EDTA K2 plasma using an automated liquid–liquid extraction. [source, 2015]
The lower limit of quantification of the analytical method for d-threo-methylphenidate was 0.15, 0.15, and 0.05 ng/mL for the 54, 36 and 18 mg doses, respectively. [source, 2015]
The upper limit of quantification of the analytical method for d-threo-methylphenidate was 30, 30, and 10 ng/mL for the 54, 36, and 18 mg doses, respectively. [source, 2015]
Evaluations were based on pharmacokinetic parameters (AUC0–, AUC0-inf, Cmax, residual area: calculated as 100*(1 − AUC0–/AUC0–inf), Tmax, Cmax, T½el, and Kel) of d-threo-methylphenidate, which were calculated using Bioequiv (version 3.50, Anapharm, Montreal, QC, Canada) software, developed and tested for bioequivalence studies. [source, 2015]
(1992), a sample size of 20 subjects was estimated to be sufficient to show bioequivalence (intra-subject coefficients of variation for AUC and Cmax for d-methylphenidate: 21% or smaller; significance level: 5%; expected deviation from the reference: 5% (point-estimate); power: 80%) with an acceptance range for the 90% confidence interval of AUC0-t and Cmax within 0.80 and 1.25 for d-threo-methylphenidate. [source, 2015]
In accordance with the protocol, bioequivalence was based on the 90% geometric confidence interval of the ratio (Sandoz MPH OCR/Concerta®) of least-squares means from the ANOVA of the ln-transformed AUC0– and Cmax falling within the range of 80% to 125% for d-threo-methylphenidate. [source, 2015]
Samples from all subjects completing the study were included in the statistical analyses for d-threo-methylphenidate. [source, 2015]
Figure2 shows the mean plasma concentration of d-threo-methylphenidate over time, after administration of Sandoz MPH OCR and Concerta® for the 18-mg fasting study. [source, 2015]
The medications included were the ones currently approved by the FDA for the treatment of ADHD: Amphetamine, Atomoxetine, Clonidine, Dexmethylphenidate, dextroAmphetamine, Guanfacine, Lisdexamfetamine, methAmphetamine, and methylphenidate. [source, 2015]